2022 NIAID Omnibus Broad Agency Announcement
Award Notice Posted
- Solicitation number
- HHS-NIH-NIAID-BAA2022-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Abviro LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93023C00055 Federal contract award
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases awarded AbViro LLC a $13,055,191 cost-reimbursement contract to advance development of a broad-spectrum flavivirus monoclonal antibody as a countermeasure against dengue virus through preparation and conduct of a Phase 2 dengue challenge clinical trial. Under the contract awarded on September 25, 2023, AbViro will conduct the clinical trial to further develop the monoclonal antibody as a countermeasure against dengue virus, which was awarded by NIAID under the 2022 NIAID Omnibus Broad Agency Announcement.
Notice text
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award. This contract is to advance the development of a broad-spectrum flavivirus mAb as a countermeasure against dengue by preparation and conduct of a Phase 2 dengue challenge clinical trial.
Awarded contract 75N93023C00055 to AbViro LLC for 13055191.00 on 2023-09-25.
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| 2022 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| 2022 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| 2022 NIAID Omnibus Broad Agency Announcement | Award Notice | |
| 2022 NIAID Omnibus Broad Agency Announcement | Solicitation | |
| 2022 NIAID Omnibus Broad Agency Announcement | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity